Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.

Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof.

Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof.

Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: (wherein A, B, C, D, T, Y and Z represent each methine or nitrogen; R1, R2, R3, R4 and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3.) The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula: 1

Abstract: A 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: 1

Abstract: The present provides a condensed pyridine compound (I) represented by the following formula: 1

Abstract: The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2 represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Abstract: Object: To provide compounds useful as inhibitors of blood platelet aggregation for intravenous administration.Constitution: A thiazoline derivative represented by the formula: ##STR1## ?wherein R.sup.1 is a hydroxyl group, an alkoxy group, a cycloalkoxy group or a group represented by the formula: R.sup.4 NH-- (wherein R.sup.4 is a cycloalkyl group), R.sup.2 is an alkyl group, a cycloalkyl group or a phenylalkyl group, R.sup.3 is a hydrogen atom or an alkyl group, and n is an integer of 2 to 9! or a salt thereof.

Abstract: A thiazoline derivative represented by the formula: ##STR1## [wherein R.sup.1 is cyano, carbamoyl, thiocarbamoyl, morpholinothiocarbonyl, alkylthioimidoyl, amidino, substituted amidino or imidazolin-2-yl, R.sup.2 is alkyl or aralkyl, R.sup.3 is hydrogen or alkyl, R.sup.4 is hydroxyl, alkoxy, substituted alkoxy or amino, l is an integer of 1 to 5] and salts thereof have fibrinogen receptor antagonism and cell adhesion factor antagonism, and are useful as therapeutic agents for ischemic diseases and atherosclerosis diseases, and metastasis inhibitory agents of tumors.

Abstract: In a speech recognition system which performs a frequency analysis of speech input and determines its spoken interval, a time-normalized pattern (matching pattern) is prepared for use in similarity calculations. In the time-normalization, the time axis is segmented in such a manner as to cancel the effects of differences in the length of syllables in the input speech. With such normalization, it is possible to achieve high performance in linear matching of the input speech pattern against reference patterns using simple processing and a small memory space even when there are variations in the speaking rate.

Abstract: In a speech recognition system using normalized spectrum matching, a second feature pattern is calculated and compared with reference patterns. The similarity obtained as a result of the comparison is used to determine overall similarity, from which the recognition is made. The second feature pattern can be a spectrum variation pattern, a level decrease pattern, or a spectrum relative value pattern.

Abstract: In a speech recognition system for effecting substantially linear matching, a start point of an input speech pattern is detected to start counting the frames of the input speech pattern for updating a speech frame number. Each time the speech frame number is updated, a plurality of frame numbers of reference templates are generated in substantially a linear relationship to the frame number, thus providing a plurality of matching paths between each of the reference templates and the input speech pattern. The distance between the input pattern data and the reference template data between the corresponding frames specified by each matching path is calculated each time the speech frame number is updated. An accumulated value of the distances along a matching path from the start point of the input speech until a desired speech frame is regarded as a dissimilarity, and the dissimilarity corresponding to each matching path in each reference template is calculated each time the speech frame is updated.

Abstract: In a speech-recognition system in which time-series patterns of characteristic quantities are extracted from an input utterance within a voiced interval, the local-peak patterns, which are the results obtained by stably extracting the characteristics of the steady vowel portions, and the consonantal patterns, which are the results obtained by stably extracting the characteristics of the consonantal portions, are recognized and identified. This makes it possible to perform accurate and stable speech-recognition including also the characteristics of the consonants.

Abstract: A method of treating or preventing hyperlipemia by administering ethanolamine derivatives. As preferable ethanolamine derivatives are mentioned N-(9,12,15,-octadecatrienoyl)-2-aminoethyl nicotinate, N-(5,8,11,14,17-eicosapentaenoyl)-2-aminoethyl nicotinate and the like. Hyperlipemia is effectively prevented or treated by administering 300-2000 mg per day of said ethanolamine derivative for adults.

Abstract: 5-Fluorouracil derivatives represented by general; formula I: ##STR1## wherein R represents an acyl group derived from an unsaturated higher fatty acid selected from the group consisting of triene higher acids, pentaene higher acids, and hexaene higher fatty acids, can be used as for inhibiting platelet aggregation and an anticancer chemotherapeutic agent. They may be mixed with a pharmaceutically acceptable carrier or a diluent to form a medicinal preparation.

Abstract: Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient are disclosed. The alkanolamine derivatives are novel compounds which possess potent platelet aggregation inhibitory activities and effective in preventing diseases such as thrombosis. As typical compounds are mentioned N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-nicotinoyl-2-aminoethyl-5,8,11,14,17-eicosapentaenoate, N-ethyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-butyl-N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-5,8,11,14,17-3-aminopropylnicotinate, (N-ethyl-N-nicotinoyl-2-aminoethyl)-5,8,11,14,17-eicosapentaenoate and the like.